Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Zai Lab Announces Approval of TIVDAK for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today…
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
– Phase 1a clinical data in healthy participants presented for both ABI-5366…